On 28 January 2010, orphan designation (EU/3/09/706) was granted by the European Commission to Medesis Pharma, France, for lithium citrate tetrahydrate (in reverse-micelle formulation) for the treatment of Huntington's disease.
Lithium citrate tetrahydrate (in reverse-micelle formulation)
|Disease / condition||
Treatment of Huntington’s disease
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.